AzTrials
AzTrials

Respiratory InfectionPhase 2/3LESSERNCT02989051

Fluid Restriction Keeps Children Dry

A Phase 2/3 study testing Restrictive fluid regimen and Liberal fluid regimen in people with Respiratory Infection and Fluid Overload, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Rationale: Fluid overload is a common complication in children who are admitted to the pediatric intensive care for mechanical ventilation. Acute lung infection is a frequent cause for admission to the PICU and forms an uniform group with a single organ failure. Read more about this study

Who is it for?
Ages 1 week to 10 years
What is being tested?
Restrictive fluid regimen and Liberal fluid regimen
Could I receive a placebo?
No, everyone receives an active treatment
How many people
34 participants
Where
1 siteNetherlands
Study dates
Sep 2016to Nov 2018
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 week to 10 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Signed informed consent by parents or legal caretakers
  • Admitted to the PICU of the Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands
  • Intubated and mechanically ventilated, with an anticipated duration of mechanical ventilation of at least 72 hours at enrolment (as judged by investigator or pediatrician on duty)
  • Patients with an acute infectious lung disease, including (suspected) viral, bacterial or fungal infection

Who cannot join

  • Patients in need of a particular fluid regimen (either restrictive or liberal) due to their medical history (e.g. cardiovascular disease and/or congenital (cyanotic) heart disease)
  • Use of previous and/or maintenance diuretic treatment
  • Ongoing (fluid) resuscitation on admission
  • Acute kidney injury with need for renal replacement therapy

Trial locations and contacts

1 site in 1 country.

Job BM van Woensel, Professor contact

0031-20-5665769

ic.kinderen@amc.nl

Sarah A Ingelse, MD contact

0031-20-5665675

s.a.ingelse@amc.nl

Netherlands1 site, 1 recruiting
  • Academic Medical Center

    Amsterdam

    Job BM van Woensel, Professor, 0031-20-566579, ic.kinderen@amc.nl

    Sarah A Ingelse, MD, 0031-20-5665675, s.a.ingelse@amc.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Fluids in Mechanically Ventilated Children With Acute Infectious Lung Disease: How Dry Should They be?

Rationale: Fluid overload is a common complication in children who are admitted to the pediatric intensive care for mechanical ventilation. Acute lung infection is a frequent cause for admission to the PICU and forms an uniform group with a single organ failure. In these critically ill children, fluid overload is associated with adverse outcome. Restricting the volume of fluids already in an early stage of ICU admission may prevent fluid overload during mechanical ventilation and thus improve clinical outcome. However, at the same time fluid restriction may interfere with appropriate energy and macronutrient intake that is needed for recovery.

Objective: The main goal of this pilot study is to evaluate the feasibility of a restrictive fluid management protocol and investigate its effect on the occurrence of fluid overload in mechanically ventilated children with acute infectious lung disease.

Read more

Study design: Single-center prospective randomized feasibility and pilot study in preparation of a multi-center randomized controlled trial (RCT).

Study population: Mechanically ventilated children with (suspicion of) acute infectious lung disease admitted to the pediatric intensive care unit (PICU) of the Emma Children's Hospital, Academic Medical Center, Amsterdam.

Intervention: Patients receive either liberal (control group) or a restrictive (experimental group) fluid treatment, while ensuring appropriate caloric intake.

Main study parameters/endpoints: Primary outcomes are cumulative fluid balance and body weight during the first week of mechanical ventilation. Secondary outcomes (in preparation of the larger multi-center RCT) include: mortality, duration of mechanical ventilation and oxygenation indices. To determine the feasibility, in- and exclusion rate, adherence to treatment arms, need for fluid bolus, need for diuretics and hemodynamic indices as well as energy and protein intake are studied.

Both fluid management protocols reflect a variant of current clinical practice, hence will not provide extra burden or risk to patients included in the study. Patients will be randomized to either of the fluid protocol arms on admission to the PICU (at start of mechanical ventilation). Patients included in the restrictive fluid treatment arm might have direct benefit from the study if indeed fluid overload is less common in this group.

Being tested
Restrictive fluid regimen, Liberal fluid regimen
Medical subject headings
Respiratory Tract Infections, Edema, Critical Illness, Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Restrictive fluid regimenOther

    In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).

  • Liberal fluid regimenOther

    This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of >85% of normal fluid recommendations (for a healthy child).

Study groups in NCT02989051
Study groupRoleWhat they receive
Restrictive fluid treatmentExperimentalRestrictive fluid regimen
Receives: Other: Restrictive fluid regimen
Liberal fluid treatmentActive comparatorThis is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
Receives: Other: Liberal fluid regimen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cumulative fluid balance

    Measured: First week of mechanical ventilation

  2. Body weight

    Measured: First week of mechanical ventilation

Secondary outcomes (3)
  1. Duration of mechanical ventilation

    Measured: Through study completion, an average of 1 week

  2. Oxygenation indices

    Measured: Through study completion, an average of 1 week

  3. Mortality

    Measured: Up to 90 days after admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2016 (estimated)
  2. Study startSep 2016
  3. Primary completionSep 2018 (estimated)
  4. Study completionNov 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
34 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02989051
Sponsor's protocol ID
2016_096
Acronym
LESSER
Status last verified
Dec 2016
First submitted
5 Dec 2016
Last updated
12 Dec 2016
Results posted
No
Data monitoring committee
No

Publications

  • Ingelse SA, Geukers VG, Dijsselhof ME, Lemson J, Bem RA, van Woensel JB. Less Is More?-A Feasibility Study of Fluid Strategy in Critically Ill Children With Acute Respiratory Tract Infection. Front Pediatr. 2019 Dec 10;7:496. doi: 10.3389/fped.2019.00496. eCollection 2019.

    PubMed 31921715

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Restrictive fluid regimen and Liberal fluid regimen in people with Respiratory Infection and Fluid Overload, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Job BM van Woensel, Professor (0031-20-5665769, ic.kinderen@amc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cumulative fluid balance (time frame: First week of mechanical ventilation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02989051, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in